ArticleBMC neurology2026
Utility of gait biomarkers in screening for obstructive sleep apnea among patients with Parkinson's disease: a cross-sectional study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundObstructive sleep apnea (OSA) is a common but often overlooked comorbidity in patients with Parkinson’s disease (PD), impacting both motor and non-motor symptoms and potentially affecting gait control. Early identification of PD with comorbid OSA (PD-OSA) is crucial for improving patient outcomes.
methodsThis study employed a wearable inertial sensor system to systematically collect spatiotemporal gait parameters and dynamic stability indicators during a standardized Timed Up and Go (TUG) test in 61 PD patients. Patients were categorized into PD-OSA and PD-NOSA groups based on apnea-hypopnea index (AHI). Linear mixed-effects models analyzed gait differences, and an Extreme Gradient Boosting (XGBoost) algorithm was used to develop a screening model integrating gait features and non-motor symptom scores.
resultsThe PD-OSA group showed significant reductions in key gait parameters including step length, stride velocity, arm swing range, and Trunk Max Sagittal Angular Velocity compared to the PD-NOSA group. The XGBoost model demonstrated excellent performance in an independent test set with an AUC of 0.944, sensitivity of 83.3%, and specificity of 83.3%. The most predictive features aligned closely with underlying pathophysiological mechanisms.
conclusionA machine learning model based on wearable-derived gait parameters and clinical scores can effectively identify PD patients with comorbid OSA noninvasively at an early stage, offering potential clinical utility to enhance comprehensive management and prognosis of PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.